Eliminating human tuberculosis in the twenty-first century

Recognizing that tuberculosis (TB) is still the leading cause of human death from a curable infection, the international health community has set ambitious targets for disease control. One target is to eliminate TB by 2050; that is, to cut the annual incidence of new cases to less than 1 per million population. National TB control programmes are working to eliminate TB mainly by intensifying efforts to find and cure patients with active disease. Here, we use mathematical modelling to show that, while most TB patients can be cured with present drug regimens, the 2050 target is far more likely to be achieved with a combination of diagnostics, drugs and vaccines that can detect and treat both latent infection and active disease. We find that the coupling of control methods is particularly effective because treatments for latent infection and active disease act in synergy. This synergistic effect offers new perspectives on the cost-effectiveness of treating latent TB infection and the impact of possible new TB vaccines. Our results should be a stimulus to those who develop, manufacture and implement new technology for TB control, and to their financial donors.

[1]  Luca Richeldi,et al.  An update on the diagnosis of tuberculosis infection. , 2006, American journal of respiratory and critical care medicine.

[2]  Ted Cohen,et al.  The effect of drug resistance on the fitness of Mycobacterium tuberculosis. , 2003, The Lancet. Infectious diseases.

[3]  S. Blower,et al.  Quantifying the intrinsic transmission dynamics of tuberculosis. , 1998, Theoretical population biology.

[4]  S. Blower,et al.  Control Strategies for Tuberculosis Epidemics: New Models for Old Problems , 1996, Science.

[5]  S. Kalantri,et al.  New tools and emerging technologies for the diagnosis of tuberculosis: Part I. Latent tuberculosis , 2006, Expert review of molecular diagnostics.

[6]  M. Raviglione The Global Plan to Stop TB, 2006-2015. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[7]  C. Murray,et al.  Modeling the impact of global tuberculosis control strategies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  C. Schechter,et al.  Interpretation of the tuberculin skin test , 1995, Journal of General Internal Medicine.

[9]  Christopher Dye,et al.  Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country , 1999 .

[10]  M. Borgdorff,et al.  New Measurable Indicator for Tuberculosis Case Detection , 2004, Emerging infectious diseases.

[11]  P. Andersen,et al.  The success and failure of BCG — implications for a novel tuberculosis vaccine , 2005, Nature Reviews Microbiology.

[12]  B G Williams,et al.  Criteria for the control of drug-resistant tuberculosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Yim,et al.  Treatment of Latent Tuberculosis Infection in Korea , 2008 .

[14]  M. Uplekar,et al.  WHO's new Stop TB Strategy , 2006, The Lancet.

[15]  P E Fine,et al.  The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection , 1997, Epidemiology and Infection.

[16]  P. Escalante Tuberculosis , 1904, Annals of Internal Medicine.

[17]  D. Cohn Treatment of latent tuberculosis infection. , 2003, Seminars in respiratory infections.

[18]  V. Krishna,et al.  Interpretation of the tuberculin skin test. , 2009, Journal of the National Medical Association.

[19]  C. Dye,et al.  Targets for global tuberculosis control. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[20]  M. Pai,et al.  The prognosis of latent tuberculosis: can disease be predicted? , 2007, Trends in molecular medicine.

[21]  G W Comstock,et al.  Epidemiology of tuberculosis. , 1982, The American review of respiratory disease.

[22]  C. Dye,et al.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. , 1999, JAMA.

[23]  Richard D Moore,et al.  Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. , 2006, American journal of respiratory and critical care medicine.

[24]  C. Dye Global epidemiology of tuberculosis , 2006, The Lancet.

[25]  Brian G. Williams,et al.  Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis , 2002, Science.

[26]  O. Diekmann,et al.  Mathematical Epidemiology of Infectious Diseases: Model Building, Analysis and Interpretation , 2000 .

[27]  R. May,et al.  Infectious Diseases of Humans: Dynamics and Control , 1991, Annals of Internal Medicine.

[28]  T. Frieden,et al.  Trends in the prevalence and incidence of tuberculosis in south India. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[29]  S. Blower,et al.  The intrinsic transmission dynamics of tuberculosis epidemics , 1995, Nature Medicine.

[30]  D. Jamison,et al.  Tuberculosis -- Disease Control Priorities in Developing Countries , 2006 .

[31]  J. Stockman Effect of BCG Vaccination on Childhood Tuberculous Meningitis and Miliary Tuberculosis Worldwide: A Meta-analysis and Assessment of Cost-effectiveness , 2007 .

[32]  C. Dye,et al.  Tuberculosis control in the era of HIV , 2005, Nature Reviews Immunology.

[33]  R. Horsburgh,et al.  Priorities for the treatment of latent tuberculosis infection in the United States. , 2004, The New England journal of medicine.

[34]  C. Dye,et al.  The Development and Impact of Tuberculosis Vaccines , 2006, Cell.

[35]  L. Tanoue Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis , 2008 .

[36]  P E Fine,et al.  The long-term dynamics of tuberculosis and other diseases with long serial intervals: implications of and for changing reproduction numbers , 1998, Epidemiology and Infection.

[37]  John G. Bartlett Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient , 2004, The Lancet.

[38]  Joshua A. Salomon,et al.  World mortality in 2000: life tables for 191 countries. , 2002 .

[39]  G. Bai,et al.  Worldwide Emergence of Extensively Drug-resistant Tuberculosis , 2007, Emerging infectious diseases.

[40]  Graham R. Stewart,et al.  Tuberculosis: a problem with persistence , 2003, Nature Reviews Microbiology.

[41]  Christopher Dye,et al.  Prospects for worldwide tuberculosis control under the WHO DOTS strategy , 1998, The Lancet.

[42]  C. Dye,et al.  Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness , 2006, The Lancet.

[43]  Alan D. Lopez,et al.  Global burden of disease and risk factors , 2006 .